{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:38:38Z","timestamp":1789958318286,"version":"4.0.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,3,5]]},"DOI":"10.1038\/s41416-025-03321-w","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T12:09:19Z","timestamp":1766750959000},"page":"764-771","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of tislelizumab combined with chemotherapy for locally advanced penile cancer: a prospective, single-arm clinical study"],"prefix":"10.1038","volume":"134","author":[{"given":"Xingli","family":"Shan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongsong","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houshan","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengming","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijia","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donglin","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9874-888X","authenticated-orcid":false,"given":"Jingke","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1449-9626","authenticated-orcid":false,"given":"Linjun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"key":"3321_CR1","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.26633\/rpsp.2017.117","volume":"41","author":"CE Montes Cardona","year":"2017","unstructured":"Montes Cardona CE, Garc\u00eda-Perdomo HA. Incidence of penile cancer worldwide: systematic review and meta-analysis. Rev Panam Salud Publica. 2017;41:e117 https:\/\/doi.org\/10.26633\/rpsp.2017.117.","journal-title":"Rev Panam Salud Publica"},{"key":"3321_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00345-008-0302-z","volume":"27","author":"MC Bleeker","year":"2009","unstructured":"Bleeker MC, Heideman DA, Snijders PJ, Horenblas S, Dillner J, Meijer CJ. Penile cancer: epidemiology, pathogenesis and prevention. World J Urol. 2009;27:141\u201350.","journal-title":"World J Urol"},{"key":"3321_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41572-021-00246-5","volume":"7","author":"A Thomas","year":"2021","unstructured":"Thomas A, Necchi A, Muneer A, Tobias-Machado M, Tran ATH, Van Rompuy AS, et al. Penile cancer. Nat Rev Dis Prim. 2021;7:11.","journal-title":"Nat Rev Dis Prim"},{"key":"3321_CR4","unstructured":"Guo YL, Na YQ, Ye ZQ, Huang J, Zhang X, Wei Qiang, et al. The 2022 Chinese guideline for the diagnosis and treatment of urological and andrological diseases. Science and Technology Press, 2022:245\u201371."},{"key":"3321_CR5","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1097\/JU.0000000000000746","volume":"203","author":"M Azizi","year":"2020","unstructured":"Azizi M, Aydin AM, Hajiran A, Lai A, Kumar A, Peyton CC, et al. Systematic review and meta-analysis-is there a benefit in using neoadjuvant systemic chemotherapy for locally advanced penile squamous cell carcinoma?. J Urol. 2020;203:1147\u201355.","journal-title":"J Urol"},{"key":"3321_CR6","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.urology.2014.12.049","volume":"85","author":"J Wang","year":"2015","unstructured":"Wang J, Pettaway CA, Pagliaro LC. Treatment for metastatic penile cancer after first-line chemotherapy failure: analysis of response and survival outcomes. Urology. 2015;85:1104\u201310.","journal-title":"Urology"},{"key":"3321_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.humpath.2016.09.003","volume":"59","author":"M Cocks","year":"2017","unstructured":"Cocks M, Taheri D, Ball MW, Bezerra SM, Del Carmen Rodriguez M, Ricardo BFP, et al. Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort. Hum Pathol. 2017;59:55\u201361.","journal-title":"Hum Pathol"},{"key":"3321_CR8","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s10637-021-01100-x","volume":"39","author":"AW Hahn","year":"2021","unstructured":"Hahn AW, Chahoud J, Campbell MT, Karp DD, Wang J, Stephen B, et al. Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial. Invest N Drugs. 2021;39:1405\u201310.","journal-title":"Invest N Drugs"},{"key":"3321_CR9","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1177\/1078155220922602","volume":"27","author":"A Baweja","year":"2021","unstructured":"Baweja A, Mar N. Metastatic penile squamous cell carcinoma with dramatic response to combined checkpoint blockade with ipilimumab and nivolumab. J Oncol Pharm Pr. 2021;27:212\u20135.","journal-title":"J Oncol Pharm Pr"},{"key":"3321_CR10","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40265-020-01286-z","volume":"80","author":"A Lee","year":"2020","unstructured":"Lee A, Keam SJ. Tislelizumab: First Approval. Drugs. 2020;80:617\u201324.","journal-title":"Drugs"},{"key":"3321_CR11","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00262-018-2160-x","volume":"67","author":"T Zhang","year":"2018","unstructured":"Zhang T, Song X, Xu L, Ma J, Zhang Y, Gong W, et al. The binding of an anti-PD-1 antibody to Fc\u03b3R\u0399 has a profound impact on its biological functions. Cancer Immunol Immunother. 2018;67:1079\u201390.","journal-title":"Cancer Immunol Immunother"},{"key":"3321_CR12","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/jamaoncol.2021.0366","volume":"7","author":"J Wang","year":"2021","unstructured":"Wang J, Lu S, Yu X, Hu Y, Sun Y, Wang Z, et al. Tislelizumab Plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a Phase 3 randomized clinical trial. JAMA Oncol. 2021;7:709\u201317.","journal-title":"JAMA Oncol"},{"key":"3321_CR13","doi-asserted-by":"publisher","first-page":"4542","DOI":"10.1158\/1078-0432.CCR-19-3561","volume":"26","author":"J Xu","year":"2020","unstructured":"Xu J, Bai Y, Xu N, Li E, Wang B, Wang J, et al. Tislelizumab plus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma and gastric\/gastroesophageal junction adenocarcinoma. Clin Cancer Res. 2020;26:4542\u201350.","journal-title":"Clin Cancer Res"},{"key":"3321_CR14","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3321_CR15","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Penile Cancer (Version 1. 2026). 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/penile.pdf."},{"key":"3321_CR16","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.mayocp.2020.06.031","volume":"96","author":"J Chahoud","year":"2021","unstructured":"Chahoud J, Kohli M, Spiess PE. Management of Advanced Penile Cancer. Mayo Clin Proc. 2021;96:720\u201332.","journal-title":"Mayo Clin Proc"},{"key":"3321_CR17","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.urolonc.2020.08.001","volume":"40","author":"J Chahoud","year":"2022","unstructured":"Chahoud J, Tamil M, Necchi A. Second line salvage systemic therapy for advanced penile cancer. Urol Oncol. 2022;40:229\u201334.","journal-title":"Urol Oncol"},{"key":"3321_CR18","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/ncpuro0751","volume":"4","author":"G Novara","year":"2007","unstructured":"Novara G, Galfano A, De Marco V, Artibani W, Ficarra V. Prognostic factors in squamous cell carcinoma of the penis. Nat Clin Pr Urol. 2007;4:140\u20136.","journal-title":"Nat Clin Pr Urol"},{"key":"3321_CR19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.eururo.2008.04.016","volume":"54","author":"JA Leijte","year":"2008","unstructured":"Leijte JA, Kirrander P, Antonini N, Windahl T, Horenblas S. Recurrence patterns of squamous cell carcinoma of the penis: recommendations for follow-up based on a two-centre analysis of 700 patients. Eur Urol. 2008;54:161\u20138.","journal-title":"Eur Urol"},{"key":"3321_CR20","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/MOU.0000000000000714","volume":"30","author":"HM de Vries","year":"2020","unstructured":"de Vries HM, Ottenhof SR, van der Heijden MS, Pos FJ, Horenblas S, Brouwer OR. Management of the penile squamous cell carcinoma patient after node positive radical inguinal lymph node dissection: current evidence and future prospects. Curr Opin Urol. 2020;30:223\u20138.","journal-title":"Curr Opin Urol"},{"key":"3321_CR21","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1200\/JCO.2010.29.5477","volume":"28","author":"LC Pagliaro","year":"2010","unstructured":"Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol. 2010;28:3851\u20137.","journal-title":"J Clin Oncol"},{"key":"3321_CR22","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1038\/bjc.2013.620","volume":"109","author":"S Nicholson","year":"2013","unstructured":"Nicholson S, Hall E, Harland SJ, Chester JD, Pickering L, Barber J, et al. Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK\/09\/001). Br J Cancer. 2013;109:2554\u20139.","journal-title":"Br J Cancer"},{"key":"3321_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5847-2","volume":"19","author":"J Xu","year":"2019","unstructured":"Xu J, Li G, Zhu SM, Cai QL, Wang Z, Yang X, et al. Neoadjuvant docetaxel, cisplatin and ifosfamide (ITP) combination chemotherapy for treating penile squamous cell carcinoma patients with terminal lymph node metastasis. BMC Cancer. 2019;19:625.","journal-title":"BMC Cancer"},{"key":"3321_CR24","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/bju.12946","volume":"117","author":"RJ Dickstein","year":"2016","unstructured":"Dickstein RJ, Munsell MF, Pagliaro LC, Pettaway CA. Prognostic factors influencing survival from regionally advanced squamous cell carcinoma of the penis after preoperative chemotherapy. BJU Int. 2016;117:118\u201325.","journal-title":"BJU Int"},{"key":"3321_CR25","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","volume":"14","author":"S Zhu","year":"2021","unstructured":"Zhu S, Zhang T, Zheng L, Liu H, Song W, Liu D, et al. Combination strategies to maximize the benefits of cancer immunotherapy. J Hematol Oncol. 2021;14:156.","journal-title":"J Hematol Oncol"},{"key":"3321_CR26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.canlet.2019.02.048","volume":"452","author":"WD Yu","year":"2019","unstructured":"Yu WD, Sun G, Li J, Xu J, Wang X. Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and\/or chemotherapy. Cancer Lett. 2019;452:66\u201370.","journal-title":"Cancer Lett"},{"key":"3321_CR27","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, Souli\u00e8res D, Tahara M, de Castro G Jr., et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394:1915\u201328.","journal-title":"Lancet"},{"key":"3321_CR28","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1093\/jnci\/djad155","volume":"115","author":"T El Zarif","year":"2023","unstructured":"El Zarif T, Nassar AH, Pond GR, Zhuang TZ, Master V, Nazha B, et al. Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors. J Natl Cancer Inst. 2023;115:1605\u201315.","journal-title":"J Natl Cancer Inst"},{"key":"3321_CR29","doi-asserted-by":"publisher","unstructured":"Cotait Maluf F, Trindade K, Preto D, de Almeida Luz M, Medeiros Milhomem Beato P, Assed Bastos D, et al. Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With Advanced Penile Cancer: The Nonrandomized HERCULES (LACOG 0218) Clinical Trial. JAMA Oncol. 2025 e253266. https:\/\/doi.org\/10.1001\/jamaoncol.2025.3266.","DOI":"10.1001\/jamaoncol.2025.3266"},{"key":"3321_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2025.101185","volume":"55","author":"U Dhasthakeer","year":"2025","unstructured":"Dhasthakeer U, Jha AN, Gupta AK. Comparison of efficacy and toxicity of chemotherapeutic regimens used as adjuvant and\/or neoadjuvant chemotherapy in penile cancer patients. Curr Probl Cancer. 2025;55:101185.","journal-title":"Curr Probl Cancer"},{"key":"3321_CR31","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.ccell.2025.03.023","volume":"43","author":"X An","year":"2025","unstructured":"An X, Guo SJ, Yan R, Xue T, Xiong LB, Ma HL, et al. Neoadjuvant toripalimab plus nimotuzumab combined with taxol-based chemotherapy in locally advanced penile squamous cell carcinoma. Cancer Cell. 2025;43:970\u201380.e973. https:\/\/doi.org\/10.1016\/j.ccell.2025.03.023.","journal-title":"Cancer Cell"},{"key":"3321_CR32","doi-asserted-by":"publisher","first-page":"848","DOI":"10.21037\/tau.2017.03.92","volume":"6","author":"W Gu","year":"2017","unstructured":"Gu W, Zhu Y, Ye D. Beyond chemotherapy for advanced disease-the role of EGFR and PD-1 inhibitors. Transl Androl Urol. 2017;6:848\u201354.","journal-title":"Transl Androl Urol"},{"key":"3321_CR33","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1093\/annonc\/mdw216","volume":"27","author":"AM Udager","year":"2016","unstructured":"Udager AM, Liu TY, Skala SL, Magers MJ, McDaniel AS, Spratt DE, et al. Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches. Ann Oncol. 2016;27:1706\u201312.","journal-title":"Ann Oncol"},{"key":"3321_CR34","first-page":"249","volume":"14","author":"T Xue","year":"2022","unstructured":"Xue T, Yan R, Han H. Research progress of immune microenvironment and immunotherapy of penile cancer. J Contemp Urol Reprod Oncol. 2022;14:249\u201352.","journal-title":"J Contemp Urol Reprod Oncol"},{"key":"3321_CR35","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1016\/S0022-5347(05)68815-5","volume":"161","author":"GP Haas","year":"1999","unstructured":"Haas GP, Blumenstein BA, Gagliano RG, Russell CA, Rivkin SE, Culkin DJ, et al. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. J Urol. 1999;161:1823\u20135.","journal-title":"J Urol"},{"key":"3321_CR36","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s00432-014-1720-5","volume":"140","author":"B Zou","year":"2014","unstructured":"Zou B, Han Z, Wang Z, Bian J, Xu J, Wang H, et al. Neoadjuvant therapy combined with a BMP regimen for treating penile cancer patients with lymph node metastasis: a retrospective study in China. J Cancer Res Clin Oncol. 2014;140:1733\u20138.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3321_CR37","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/S0022-5347(01)62402-9","volume":"160","author":"DA Corral","year":"1998","unstructured":"Corral DA, Sella A, Pettaway CA, Amato RJ, Jones DM, Ellerhorst J. Combination chemotherapy for metastatic or locally advanced genitourinary squamous cell carcinoma: a phase II study of methotrexate, cisplatin and bleomycin. J Urol. 1998;160:1770\u20134.","journal-title":"J Urol"},{"key":"3321_CR38","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/S0022-5347(17)38069-2","volume":"146","author":"FH Dexeus","year":"1991","unstructured":"Dexeus FH, Logothetis CJ, Sella A, Amato R, Kilbourn R, Fitz K, et al. Combination chemotherapy with methotrexate, bleomycin and cisplatin for advanced squamous cell carcinoma of the male genital tract. J Urol. 1991;146:1284\u20137.","journal-title":"J Urol"},{"key":"3321_CR39","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29518","volume":"14","author":"KM Hamed","year":"2022","unstructured":"Hamed KM, Dighriri IM, Baomar AF, Alharthy BT, Alenazi FE, Alali GH, et al. Overview of Methotrexate Toxicity: A Comprehensive Literature Review. Cureus. 2022;14:e29518. https:\/\/doi.org\/10.7759\/cureus.29518.","journal-title":"Cureus"},{"key":"3321_CR40","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1517\/14740338.6.5.609","volume":"6","author":"NI Marupudi","year":"2007","unstructured":"Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM, Brem H. Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf. 2007;6:609\u201321.","journal-title":"Expert Opin Drug Saf"},{"key":"3321_CR41","unstructured":"EAU-ASCO Collaborative Guidelines on Penile Cancer. 2025. https:\/\/uroweb.org\/guidelines\/penile-cancer."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03321-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03321-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03321-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T09:21:12Z","timestamp":1770974472000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03321-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,3,5]]}},"alternative-id":["3321"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03321-w","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]},"assertion":[{"value":"28 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Ethics Committee of Beijing Chaoyang Huanxing Cancer Hospital (approval no. 2020-10), and the study was conducted following the Declaration of Helsinki, Good Clinical Practice Guidelines, and Chinese regulatory requirements. Written informed consent was obtained from all patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}